Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations

• Published in: Neuropathology and applied neurobiology Vol. 31; no. 4; pp. 384 - 394
• Main Authors: Arjona, D., Bello, M. J., Alonso, M. E., Aminoso, C., Isla, A., De Campos, J. M., Sarasa, J. L., Gutierrez, M., Villalobo, A., Rey, J. A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01-08-2005; Blackwell Science
• Subjects: astrocytic gliomas; Astrocytoma - genetics; Base Sequence; Biological and medical sciences; Blotting, Southern; Brain Neoplasms - genetics; Diseases of striated muscles. Neuromuscular diseases; DNA Mutational Analysis; EGFR; Epidermal Growth Factor - genetics; Gene Amplification; gene rearrangements; genomic mutations; Humans; Medical sciences; Molecular Sequence Data; Mutation; Neurology; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - analysis; Tumors of the nervous system. Phacomatoses; Nervous system diseases; genomic mutations; Neuroglia; Alteration; Astrocyte; Gene expression; EGFR; Polymerase chain reaction; Gene amplification; Glioma; DNA; Central nervous system disease; Gene rearrangement; Tumor; gene rearrangements; Mutation; astrocytic gliomas; Quantitative analysis
• ISSN: 0305-1846; 1365-2990
• DOI: 10.1111/j.1365-2990.2005.00653.x

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with tyrosine kinase activity. This report investigates the presence of mutations, amplification and/or over‐expression of the EGFR gene in 86 glial tumours including 44 glioblastomas, 21 anaplastic astrocytomas, and 21 WHO grade II astrocytomas, using polymerase chain reaction/single‐strand conformation polymorphism, semiquantitative reverse‐transcription‐polymerase chain reaction (RT‐PCR) and Southern Blot techniques. Gene amplification values were found in 34 tumours. Amplification levels were not uniform, as the transmembrane region presented lower amplification rates than extra‐ and intracellular domains. For the 19 samples with sufficient available tumour tissue we found over‐expression in 11, and no EGFR mRNA expression in three. Ten cases showed deletion transcripts, and EGFR VIII was identified in all of these cases. One of the cases with EGFR vIII also presented a truncated form, C‐958, while another showed an in frame tandem duplication of exons 18–25. We found 14 cases with sequence/structure gene alterations, including seven on which genomic novel DNA changes were identified: a missense mutation (1052C > T/Ala265Val), an insertion (InsCCC2498/Ins Pro748), three intronic changes (E6 + 72delG, E22–14C > G and E18–109T > C), a new polymorphic variant E12 + 22A > T, and one case that presented a 190 bp insertion, that was produced by the intron‐7–exon‐8 duplication and generated a truncated EGFR with intact exons 1–8 followed by an additional amino acidic sequence: Val‐Ile‐Met‐Trp. These findings corroborate that EGFR is non‐randomly involved in malignant glioma development and that different mutant forms participate in aberrant activation of tyrosine kinase pathways.